- Conditions
- Brain Tumor
- Interventions
- Asciminib, Sildenafil, Surgical resection or biopsy
- Drug · Procedure
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years to 39 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–8
of 8
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Riociguat (Adempas, BAY63-2521), Sildenafil, Tadalafil
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 225 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 17
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Sacramento, California + 14 more
- Conditions
- Cancer
- Interventions
- Sildenafil
- Drug
- Lead sponsor
- The University of Texas Medical Branch, Galveston
- Other
- Eligibility
- 30 Years to 50 Years · Female only
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027 – 2030
- U.S. locations
- 1
- States / cities
- Galveston, Texas
- Conditions
- Choroidal Ischemia, Vitelliform Macular Dystrophy, Age-related Macular Degeneration, Central Serous Retinopathy, Retinitis Pigmentosa
- Interventions
- Sildenafil, Standard of Care Sildenafil, Ocular Coherence Tomography-Angiography (OCT-A), Visual Acuity (VA)
- Drug · Other · Diagnostic Test
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2020
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Pulmonary Hypertension
- Interventions
- Obtain blood specimens
- Procedure
- Lead sponsor
- Children's Hospital of Philadelphia
- Other
- Eligibility
- 28 Days and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Prostate Cancer
- Interventions
- Alprostadil (E1), Papaverine, Phentolamine mesylate, Sildenafil citrate, conventional surgery
- Drug · Procedure
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- Up to 65 Years · Male only
- Enrollment
- 111 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2009
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Prostate Cancer, Erectile Dysfunction Following Radical Prostatectomy, Erectile Dysfunction Following Simple Prostatectomy, Erectile Dysfunction
- Interventions
- Cognitive-behavioral Meetings, sildenafil citrate, Vacuum Constriction Device
- Behavioral · Drug · Device
- Lead sponsor
- Case Comprehensive Cancer Center
- Other
- Eligibility
- 21 Years and older · Male only
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Persistent Pulmonary Hypertension of the Newborn
- Interventions
- 1 dose of sildenafil
- Drug
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- Up to 364 Days
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 9
- States / cities
- Birmingham, Alabama • Indianapolis, Indiana • Louisville, Kentucky + 6 more